Benjamin Halladay Esperion Therapeutics, Inc. (ESPR) insider trading activity
Benjamin Halladay is Chief Financial Officer of Esperion Therapeutics, Inc.. Currently has a direct ownership of 240,682 shares of ESPR, which is worth approximately $454,888. The most recent transaction as insider was on Jan 17, 2025, when has been sold 9 shares (Common Stock) at a price of $2.27 per share, resulting in proceeds of $20. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).
Shares Held (Direct Ownership)
241K
1.33%
3M change
225.53%
12M change
Total Value Held
$454,888
Benjamin Halladay Transaction History
BH
Benjamin Halladay
Chief Financial Officer
Ann Arbor, MI